With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a | ...
It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...
There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division. | There’s no need to dive fast and furious ...
In its 100th year in operation, family-run Recordati is considering a buyout offer from CVC Capital Partners. | CVC Capital ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...
After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...
With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results